This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
These 3 Medical Stocks Have Wall Street's Bullish Vote for 2026
by Kaibalya Pravo Dey
COR, ADUS and SEM earn bullish analyst support for 2026 as AI adoption, home care demand and facility expansion fuel medical sector growth.
medical pharmaceuticals
Company News for Dec 24, 2025
by Zacks Equity Research
Companies In The News Are: NVO, HII, NOW, ZIM.
aerospace computers pharmaceuticals transportation
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
by Ekta Bagri
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
biotechnology biotechs medical pharmaceuticals
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
by Sundeep Ganoria
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
biotechs medical pharmaceuticals vaccines
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
by Zacks Equity Research
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso
by Zacks Equity Research
Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.
computers finance medical-devices oil-energy pharmaceuticals
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Big Drug Stocks That May Continue to Outperform in 2026
by Kinjel Shah
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
biotechs pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
biotechs medical pharmaceuticals
Top Analyst Reports for Eli Lilly, Shell & ICICI Bank
by Mark Vickery
LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup.
computers finance medical-devices oil-energy pharmaceuticals